Peptide Comparison
GHRP-2 vs Hexarelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.
Data-derived verdict
GHRP-2 and Hexarelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Japan-Approved Diagnostic / Phase 2 (not approved)). On the catalogued data layer Hexarelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Hexarelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: cortisol. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| GHRP-2 | Hexarelin | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | GHRP; potent ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; strong GH release | GHS-R1a agonist; more potent GH release than other GHRPs |
| Route | SC / Intranasal | SC / Intranasal |
| Half-life | ~15-30 min | ~1 hr |
| Dosage (research) | 100-300 mcg SC 1-3x daily | 100-200 mcg SC 1-2x daily (short cycles) |
| Evidence tier | Japan-Approved Diagnostic | Phase 2 (not approved) |
| Research depth | 148 indexed | 158 indexed |
| Availability | Research | Research Chemical |
| Reported risks | Cortisol/prolactin increase; hunger; water retention | Cortisol/prolactin elevation; pituitary desensitization |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-2 or Hexarelin?
GHRP-2 and Hexarelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Japan-Approved Diagnostic / Phase 2 (not approved)). On the catalogued data layer Hexarelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Hexarelin's evidence base is currently denser.
What is the difference between GHRP-2 and Hexarelin?
GHRP-2 is classed as GHRP; ghrelin receptor agonist; Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: GHRP-2, GHS-R1a agonist; strong GH release; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: GHRP-2, ~15-30 min; Hexarelin, ~1 hr. Routes in published studies: GHRP-2, SC / Intranasal; Hexarelin, SC / Intranasal.
Which has stronger evidence, GHRP-2 or Hexarelin?
Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.
Which is more accessible, GHRP-2 or Hexarelin?
Neither GHRP-2 nor Hexarelin is an FDA-approved drug. Catalog status: GHRP-2, Research; Hexarelin, Research Chemical. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-2 and Hexarelin ever combined?
GHRP-2 and Hexarelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…